#### 10th March 2016

### Food retailing

### Casino Guichard

### Price EUR47.10

Bloomberg Reuters 12-month High , Market Cap (EU Ev (BG Estimate Avg. 6m daily vo 3y EPS CAGR	JR) es) (EUR)		CO FP CASP.PA 87.3 / 35.2 5,332 15,685 818.9 -12.7%		
	1 M	3 M	6 M 31	l/12/15	
Absolute perf.	12.7%	-0.4%	-14.0%	11.0%	
Food Retailing	8.6%	2.2%	-0.3%	2.9%	
DJ Stoxx 600	9.6%	-6.9%	-6.8%	-7.3%	
YEnd Dec. (EURm)	2014	2015e	2016e	2017e	
Sales	48,492	46,145	43,171	45,457	
% change		-4.8%	-6.4%	5.3%	
EBITDA	3,191	2,418	2,332	2,552	
EBIT	1,737	1,578	1,477	1,594	
% change		-9.2%	-6.4%	8.0%	
Net income	556.0	327.0	335.2	393.6	
% change		-41.2%	2.5%	17.4%	
	2014	2015e	2016e	2017e	
Operating margin	4.6	3.3	3.4	3.5	
Net margin	1.1	0.7	0.8	0.9	
ROE	NM	NM	NM	NM	
ROCE	7.1	4.7	4.6	5.0	
Gearing	37.3	36.1	35.5	33.6	
(EUR)	2014	2015e	2016e	2017e	
EPS	4.43	2.36	2.43	2.95	
% change	-	-46.7%	3.1%	21.2%	
P/E	10.6x	19.9x	19.3x	16.0x	
FCF yield (%)	13.0%	8.3%	11.1%	14.9%	
Dividends (EUR)	3.12	3.12	3.12	3.12	
Div yield (%)	6.6%	6.6%	6.6%	6.6%	
EV/Sales	0.4x	0.3x	0.3x	0.3x	
EV/EBITDA	5.7x	6.5x	6.5x	6.0x	
EV/EBIT	10.4x	9.9x	10.2x	9.6x	



### Postview: waiting for S&P...

Fair Value EUR57 (+21%)

We have to admit we were somewhat frustrated by the FY analyst meeting. Bearing in mind arguments brought forward recently by investors attacking the company (1/ the "unbearable" complexity of the group; 2/ the constrained circulation of cash within the "holding"; 3/ the anxiogenic level of debt which has translated into a very stretched level of proportionate credit ratio; 4/ and lastly, the opportunity cost in terms of long term growth and FCF following the disposal of Big C), we find that management remained tight lipped as to its intentions going forward.

Given management's philosophy which has often been to sell high mature assets and buy low promising GEMs despite the economic crises taking place in these GEMs (Growth Emerging Markets), we thought that the current depressed share prices of listed LatAm assets would have been an opportunity to do the same again (Casino is to sell its asset in Thailand for EUR3.1bn and could finally overcome the target of disposals which is for EUR4bn). In our latest report, we thus described the scenario by which Casino would have taken the full control of its LatAm assets (see our latest report (19/02/2016): With hindsight, a real Catch-22!), thus dramatically simplifying the structure of the group and the circulation of cash within the company, while maintaining the necessary conditions for long term growth (see our report – Anorexic growth... the bigger the better! / management kept saying that Brazil has huge potential going forward).

Frankly, and bluntly, following the meeting with management, we do not feel this scenario is very likely in the short term. There were many questions regarding such a scenario during the meeting and management rather closed the door for the next 12/18 months while insisting that the cash proceeds from disposals will be used to pay both gross and net debt down. Is it a circumstantial posture ahead of S&P's rating decision (which, ultimately, would not surprise us) or is it a firm and definitive "no"...? The only thing we know is that S&P has a rather disastrous outlook regarding Brazil in the short and medium term and that Casino is very committed to its investment grade status. Stay tuned.

But we do not want to let deception build up whereas management also brought encouraging indications when it comes to France (as a reminder, post disposal of Asia, the domestic market could represent up to 70% of proportionate EBITDA and should become the major factor to monitor in 2016). Beyond current trading (up +4.4% LFL at Géant and +5.2% at LP over the last nine weeks), management indicated that revenues from real estate included in EBITDA should be around EUR66m in 2016 (vs ~EUR140m expected by the consensus, EUR167m in 2015 and EUR162m in 2014), pointing to a +50% improvement of the retail underlying operating profit (i.e. excluding revenue from real estate) to ~EUR830m in 2016 (vs +30% initially expected). Clearly, the guidance seems rather bullish to us, but the optimism of the management tends to prove that France is gaining momentum and rather close to profit recovery after two years of prices investment (for a total consideration of EUR600/700m).

The repositioning of Géant, which brought visible benefits more than two years after the price initiative was launched, illustrates the timescale specific to the sector. In its Retail Journal (vol. 1), consultancy firm Oliver Wyman addresses the case of a US retailer whose volumes surged three years after it slashed its prices. This, along with several other cases, leads the firm to conclude that: 1/ in the wake of price reductions, the bulk of the resulting benefits appear only after a significant period has lapsed (>1 year); 2/ the upturn in volumes is not restricted to the products subject to the biggest price cuts, but affects the store as a whole; 3/ the increase in volumes during the months following a wave of price cuts represents on average less than 40% of the potential gain. Hence we remain reasonably optimistic when it comes to France!

### VALUATION

The sacrosanct spot SOTP currently stands at EUR48

### NEXT CATALYSTS

S&P decision regarding a potential downgrade to non-investment grade (by mid-April)

### Click here to download



Analyst : Antoine Parison 33(0) 1 70 36 57 03 aparison@bryangarnier.com Sector Team : Nikolaas Faes Loïc Morvan Cédric Rossi Virginie Roumage

### BRYAN, GARNIER & CO

BUY

## Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a
	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

#### Distribution of stock ratings

BUY ratings 64.4%

NEUTRAL ratings 28.1%

SELL ratings 7.4%

# Research Disclosure Legend

1	Bryan Garnier shareholding in Issuer	Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").	No
2	Issuer shareholding in Bryan Garnier	The Issuer has a shareholding that exceeds 5% of the paid up and issued share capital of one or more members of the Bryan Garnier Group.	No
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

### BRYAN, GARNIER & CO

London	Paris	New York	Geneva	New Delhi	
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel	
15 St. Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath	
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001	
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062	
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119	
Authorised and regulated by the	Financial Conduct Authority (FCA) and		Regulated by the	Fax +91 11 2621 9062	
Financial Conduct Authority	the Autorité de Contrôle prudential et de		FINMA		
(FCA)	resolution (ACPR)				

### Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm or an associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever. Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.

### BRYAN, GARNIER & CO